Core Insights - The research conducted by Professor Xia Ning Shao's team at Xiamen University focuses on the ten-year protective effect and immune durability of the domestically developed bivalent HPV vaccine "Xinkening" [1] Group 1: Vaccine Efficacy - The bivalent HPV vaccine "Xinkening," developed in collaboration with Wantai Biological Pharmacy, was approved for market in 2019, making it the first HPV vaccine in China and the fourth globally [1] - Previous studies indicated a 100% protection rate against HPV-16/18 related high-grade precancerous lesions within 5.5 years post-vaccination, and a 97.3% protection rate against related six-month persistent infections [1] - The ten-year study shows an 87.4% protection rate against related high-grade precancerous lesions and a 97.0% protection rate against related six-month persistent infections [1] Group 2: Immune Response - Nearly all vaccinated individuals still possess HPV-16/18 neutralizing antibodies ten years post-vaccination, with levels significantly higher than those resulting from natural infection [1] - The research confirms that the "Xinkening" vaccine is effective for at least ten years and demonstrates durable immunity, supporting its widespread application [1]